Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17 2021 - 4:05PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for rare and ultra-rare diseases, today reported the
grant of non-qualified stock options to purchase an aggregate of
14,445 shares of common stock of the company and 4,815 restricted
stock units of the company’s common stock to two newly hired
non-executive officer employees of the company. The awards were
approved by the compensation committee of the company’s board of
directors and granted under the Ultragenyx Employment Inducement
Plan, with a grant date of August 16, 2021, as an inducement
material to the new employees entering into employment with
Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the
underlying shares vesting on each anniversary of the grant date,
subject to such employee being continuously employed by the company
as of such vesting dates. The stock options vest over four years,
with 25% of the shares underlying the option vesting on the first
anniversary of the grant date and the remainder vesting with
respect to 1/48th of the shares underlying the options on each
monthly anniversary thereafter, subject to such employee being
continuously employed by the company as of such vesting dates. The
stock options have a ten-year term and an exercise price of $88.00
per share, equal to the per share closing price of Ultragenyx’s
common stock on August 16, 2021.
About Ultragenyx Pharmaceutical Inc.Ultragenyx
is a biopharmaceutical company committed to bringing novel products
to patients for the treatment of serious rare and ultra-rare
genetic diseases. The company has built a diverse portfolio of
approved therapies and product candidates aimed at addressing
diseases with high unmet medical need and clear biology for
treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact Ultragenyx Investors & MediaJoshua Higa(415)
475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Sep 2023 to Sep 2024